Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

API Manufacturing: SOP for Quality Risk Management using FMEA – V 2.0

Posted on By

API Manufacturing: SOP for Quality Risk Management using FMEA – V 2.0

Standard Operating Procedure for Quality Risk Management using FMEA in API Manufacturing

Department API Manufacturing
SOP No. SOP/API/172/2025
Supersedes SOP/API/172/2022
Page No. Page 1 of 14
Issue Date 14/04/2025
Effective Date 16/04/2025
Review Date 14/04/2026

1. Purpose

To define a systematic approach for conducting Quality Risk Management (QRM) using the Failure Mode and Effects Analysis (FMEA) method in the API manufacturing facility to proactively identify, assess, and mitigate risks that could affect product quality and regulatory compliance.

2. Scope

This SOP applies to all departments involved in manufacturing, quality control, engineering, warehouse, and

quality assurance at the API manufacturing site where process or system risks need to be assessed using FMEA methodology.

3. Responsibilities

  • QA Department: Facilitates and coordinates the QRM process, maintains documentation, and monitors implementation of risk mitigation actions.
  • Functional Heads: Participate in the risk assessment exercise, provide inputs and data, and implement agreed actions.
  • Risk Assessment Team: A cross-functional group responsible for identifying failure modes, scoring risks, and defining mitigation plans.
See also  API Manufacturing: SOP for Use of Fluid Bed Dryers in API Processing - V 2.0

4. Accountability

The Head of Quality Assurance is accountable for the overall execution, compliance, and effectiveness of the QRM process using FMEA methodology.

5. Procedure

5.1 Risk Management Principles

  1. QRM shall be applied in accordance with ICH Q9 principles: risk identification, risk analysis, risk evaluation, risk control, risk communication, and risk review.
  2. FMEA shall be used as the primary tool for structured risk evaluation in process design, change control, equipment qualification, and deviation investigations.

5.2 FMEA Team Formation

  1. QA shall form a cross-functional team comprising representatives from:
    • Production
    • QA
    • QC
    • Engineering
    • Warehouse
    • Regulatory (if required)
  2. The team leader shall be from QA to ensure impartiality and coordination.

5.3 Define Scope of FMEA

  1. The objective and scope of the FMEA exercise must be defined and documented in the FMEA Worksheet (Annexure-1).
  2. Typical applications include:
    • New equipment or process introduction
    • Change in raw material supplier
    • Recurring deviations or quality failures
    • New facility or layout modifications

5.4 Identify Failure Modes and Effects

  1. The team shall list all process steps or equipment functions.
  2. For each step, potential failure modes and their possible effects shall be identified.
  3. Causes and current control mechanisms should also be documented.
See also  API Manufacturing: SOP for Cleaning of Milling Equipment - V 2.0

5.5 Risk Scoring and Risk Priority Number (RPN)

  1. Each failure mode shall be rated for:
    • Severity (S): Impact of failure on product quality (scale 1–10)
    • Occurrence (O): Likelihood of failure happening (scale 1–10)
    • Detection (D): Ability to detect failure before impact (scale 1–10)
  2. The Risk Priority Number (RPN) is calculated as: RPN = S × O × D.
  3. Based on RPN values:
    • RPN > 100 – High Risk (Immediate action)
    • RPN 50–100 – Medium Risk (Action required)
    • RPN < 50 – Low Risk (Acceptable, monitor only)

5.6 Risk Mitigation Plan

  1. For each medium and high-risk failure mode, the team shall define:
    • Recommended action
    • Responsible department
    • Timeline
    • Re-evaluation of RPN after action implementation
  2. Actions shall be tracked in the FMEA Action Tracker (Annexure-2).

5.7 Documentation and Review

  1. QA shall compile the complete FMEA report, including all worksheets, action trackers, and conclusions.
  2. The report shall be reviewed by the Site Head or designee and filed in the QRM repository.
  3. Periodic review of the effectiveness of risk control measures shall be conducted (e.g., every 12 months).

5.8 Change Control and Linkages

  1. All changes arising from risk control shall be documented through formal Change Control procedures.
  2. The FMEA outcome must be referenced in associated change control, validation, or deviation records.
See also  API Manufacturing: SOP for Monitoring of Solvent Recovery Efficiency - V 2.0

6. Abbreviations

  • QRM: Quality Risk Management
  • FMEA: Failure Mode and Effects Analysis
  • RPN: Risk Priority Number
  • QA: Quality Assurance
  • QC: Quality Control

7. Documents

  1. FMEA Worksheet (Annexure-1)
  2. FMEA Action Tracker (Annexure-2)

8. References

  • ICH Q9: Quality Risk Management
  • 21 CFR Part 211 – Subpart F: Production and Process Controls
  • EU GMP Chapter 1 – Pharmaceutical Quality System

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: FMEA Worksheet

Process Step Failure Mode Effect Severity Occurrence Detection RPN
Weighing Wrong raw material Batch failure 9 4 3 108

Annexure-2: FMEA Action Tracker

Failure Mode Action Responsible Due Date Status
Wrong raw material Implement barcode scanning Warehouse 30/04/2025 Open

Revision History:

Revision Date Revision No. Details Reason Approved By
01/01/2022 1.0 Initial release New SOP QA Head
14/04/2025 2.0 Included scoring matrix and annexures Compliance with ICH Q9 QA Head
API Manufacturing V 2.0 Tags:API batch record, API BMR, API calibration, API centrifuge, API cleaning, API crystallization, API deviation, API documentation, API drying, API equipment cleaning, API filtration, API GMP compliance, API granulation, API hold time, API impurities, API line clearance, API manufacturing, API process, API quality control, API reactor, API sampling, API solvent handling, API validation, API waste disposal, API yield

Post navigation

Previous Post: Sterile Injectable Manufacturing: SOP for Intermediate Storage of Bulk Injectable Products – V 2.0
Next Post: Biosimilars: SOP for Deviation Management During Upstream Runs – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version